An inhibitor of neuronal exocytosis (DD04107) displays long-lasting in vivo activity against chronic inflammatory and neuropathic pain

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 3, 2012, Pages 634-645

  Ponsati, Berta ^a   Carreño, Cristina ^a   Curto Reyes, Verdad ^b   Valenzuela, Belen ^c   Duart, María José ^d   Van Den Nest, Wim ^a   Cauli, Omar ^e   Beltran, Beatriz ^f   Fernandez, Jimena ^a   Borsini, Franco ^g   Caprioli, Antonio ^g   Di Serio, Stefano ^g   Veretchy, Mario ^g   Baamonde, Ana ^b   Menendez, Luis ^b   Barros, Francisco ^b   De La Pena, Pilar ^b   Borges, Ricardo ^f   Felipo, Vicente ^e   Planells Cases, Rosa ^e   Ferrer Montiel, Antonio ^d   more..

^a Sant Quintí de Mediona ^*  (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c USP Hospital San Jaime   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^f UNIVERSIDAD DE LA LAGUNA   (Spain)

^g Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; DD 04107; DICLOFENAC; MORPHINE; NALTREXONE; PALMITOYL GLUTAMYLGLUTAMYLMETHIONYLGLUTAMINYLARGINYLARGINYL AMIDE; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; EXOCYTOSIS; HYPERALGESIA; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEWBORN; NOCICEPTION; NONHUMAN; PAW EDEMA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

ANALGESICS; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CARRAGEENAN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXOCYTOSIS; HYPERALGESIA; INFLAMMATION; INJECTIONS, SUBCUTANEOUS; LIPOPEPTIDES; MALE; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; NEURALGIA; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; TIME FACTORS;

EID: 84861560216     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.190678     Document Type: Article

References (39)

1. Ahabrach H, Piedrafita B, Ayad A, El Mlili N, Errami M, Felipo V, and Llansola M (2010) Chronic hyperammonemia alters the circadian rhythms of corticosteroid hormone levels and of motor activity in rats. J Neurosci Res 88:1605-1614.
2. Aley KO, Reichling DB, and Levine JD (1996) Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience 73:259-265. (Pubitemid 26167669)
3. Argoff C (2010) The emerging use of botulinum toxins for the treatment of neuropathic pain. Pain Med 11:1750-1752.
4. Blanes-Mira C, Merino JM, Valera E, Fernández-Ballester G, Gutiérrez LM, Viniegra S, Pérez-Payá E, and Ferrer-Montiel A (2004) Small peptides patterned after the N-terminus domain of SNAP25 inhibit SNARE complex assembly and regulated exocytosis. J Neurochem 88:124-135. (Pubitemid 38030215)
5. Boix J, Cauli O, and Felipo V (2010) Developmental exposure to polychlorinated biphenyls 52, 138 or 180 affects differentially learning or motor coordination in adult rats. Mechanisms involved. Neuroscience 167:994-1003.
6. Borges R, Von Grafenstein H, and Knight DE (1989) Tissue selectivity of endothelin. Eur J Pharmacol 165:223-230. (Pubitemid 19181790)
7. Camprubí-Robles M, Planells-Cases R, and Ferrer-Montiel A (2009) Differential contribution of SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in nociceptors. FASEB J 23:3722-3733.
8. Carmichael NM, Dostrovsky JO, and Charlton MP (2010) Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain 149:316-324.
9. Covic L, Misra M, Badar J, Singh C, and Kuliopulos A (2002) Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8:1161-1165. (Pubitemid 35175972)
10. Curto-Reyes V, Llames S, Hidalgo A, Menéndez L, and Baamonde A (2010) Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 160:561-573.
11. Favre-Guilmard C, Auguet M, and Chabrier PE (2009) Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol 617:48-53.
12. García-Ayllón MS, Cauli O, Silveyra MX, Rodrigo R, Candela A, Compañ A, Jover R, Pérez-Mateo M, Martínez S, Felipo V, et al. (2008) Brain cholinergic impairment in liver failure. Brain 131:2946-2956.
13. García-Martínez C, Fernández-Carvajal A, Valenzuela B, Gomis A, Van Den Nest W, Ferroni S, Carreño C, Belmonte C, and Ferrer-Montiel A (2006) Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity. J Pain 7:735-746. (Pubitemid 44472626)
14. Ghilardi JR, Röhrich H, Lindsay TH, Sevcik MA, Schwei MJ, Kubota K, Halvorson KG, Poblete J, Chaplan SR, Dubin AE, et al. (2005) Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25:3126-3131. (Pubitemid 40463547)
15. Gold MS and Gebhart GF (2010) Nociceptor sensitization in pain pathogenesis. Nat Med 16:1248-1257.
16. Hucho T and Levine JD (2007) Signaling pathways in sensitization: toward a nociceptor cell biology. Neuron 55:365-376. (Pubitemid 47126268)
17. Huster D, Vogel A, Katzka C, Scheidt HA, Binder H, Dante S, Gutberlet T, Zschörnig O, Waldmann H, and Arnold K (2003) Membrane insertion of a lipidated ras peptide studied by FTIR, solid-state NMR, and neutron diffraction spectroscopy. J Am Chem Soc 125:4070-4079. (Pubitemid 36512300)
18. Ji RR, Samad TA, Jin SX, Schmoll R, and Woolf CJ (2002) p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36:57-68.
19. Julius DA (1979) Research and development of naltrexone: a new narcotic antagonist. Am J Psychiatry 136:782-786.
20. Kilo S, Harding-Rose C, Hargreaves KM, and Flores CM (1997) Peripheral CGRP release as a marker for neurogenic inflammation: a model system for the study of neuropeptide secretion in rat paw skin. Pain 73:201-207. (Pubitemid 27491681)
21. Menéndez L, Lastra A, Fresno MF, Llames S, Meana A, Hidalgo A, and Baamonde A (2003) Initial thermal heat hypoalgesia and delayed hyperalgesia in a murine model of bone cancer pain. Brain Res 969:102-109. (Pubitemid 36369617)
22. Menéndez L, Lastra A, Hidalgo A, and Baamonde A (2002) Unilateral hot plate test: a simple and sensitive method for detecting central and peripheral hyperalgesia in mice. J Neurosci Methods 113:91-97. (Pubitemid 33123334)
23. Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR, Lawrence GW, and Dolly JO (2009) Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 29:4981-4992.
24. Meng J, Wang J, Lawrence G, and Dolly JO (2007) Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 120:2864-2874. (Pubitemid 47394260)
25. Mika J, Rojewska E, Makuch W, Korostynski M, Luvisetto S, Marinelli S, Pavone F, and Przewlocka B (2011) The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. Neuroscience 175:358-366.
26. Pabbidi RM, Yu SQ, Peng S, Khardori R, Pauza ME, and Premkumar LS (2008) Influence of TRPV1 on diabetes-induced alterations in thermal pain sensitivity. Mol Pain 4:9.
27. Polomano RC, Mannes AJ, Clark US, and Bennett GJ (2001) A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94:293-304. (Pubitemid 33145399)
28. Premkumar LS, Qi ZH, Van Buren J, and Raisinghani M (2004) Enhancement of potency and efficacy of NADA by PKC-mediated phosphorylation of vanilloid receptor. J Neurophysiol 91:1442-1449. (Pubitemid 38250421)
29. Qerama E, Fuglsang-Frederiksen A, and Jensen TS (2010) The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol 23:602-610.
30. Siau C, Xiao W, and Bennett GJ (2006) Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 201:507-514. (Pubitemid 44344243)
31. Sprenger T and Goadsby PJ (2009) Migraine pathogenesis and state of pharmacological treatment options. BMC Med 7:71.
32. Suri A and Szallasi A (2008) The emerging role of TRPV1 in diabetes and obesity. Trends Pharmacol Sci 29:29-36.
33. Swain SM and Arezzo JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6:455-467.
34. Torgovnick J, Arsura E, Sethi NK, Hu CJ, Yuan RY, Sheu JJ, and Apfel SC (2010) Botulinum toxin for diabetic neuropathic pain: a randomized double-blind cross-over trial: botulinum toxin for neuropathic pain? Neurology 74:92-93.
35. Van Buren JJ, Bhat S, Rotello R, Pauza ME, and Premkumar LS (2005) Sensitization and translocation of TRPV1 by insulin and IGF-I. Mol Pain 1:17.
36. Yoon SH, Merrill RL, Choi JH, and Kim ST (2010) Use of botulinum toxin type A injection for neuropathic pain after trigeminal nerve injury. Pain Med 11:630-632.
37. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, and Hu CJ (2009) Botulinum toxin for diabetic neuropathic pain: a randomized double-blind cross-over trial. Neurology 72:1473-1478.
38. Zhang X, Huang J, and McNaughton PA (2005) NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 24:4211-4223. (Pubitemid 41828897)
39. Zhu J, Zou LP, Bakhiet M, and Mix E (1998) Resistance and susceptibility to experimental autoimmune neuritis in Sprague-Dawley and Lewis rats correlate with different levels of autoreactive T and B cell responses to myelin antigens. J Neurosci Res 54:373-381. (Pubitemid 28493947)